Our Approach

Ardelyx develops:

  • Drugs that target proteins found in the gut whose activities affect the entire body
  • Drugs that are not absorbed, enabling them to achieve systemic efficacy while avoiding systemic toxicity and side effects

What we do

Targeted Therapeutic Areas

Ardelyx has established a unique approach to drug development with programs targeting gut transporters, receptors, and enzymes

Therapeutic Areas

News

Ardelyx will present at the European Renal Assocation – European Dialysys and Transplant Association (ERA-EDTA) annual meeting in Paris (France) May 24-27, 2012


05/24/2012

RDX5791, a non-systemic NHE3 inhibitor for the treatment of fluid and sodium overload, shifts sodium excretion from urine to feces in healthy subjects

D.Charmot, J.W. Jacobs, A.G.Spencer, M.Raab, D.Rosenbaum



« back to news page